Quince Therapeutics is developing LAM-001, an inhaled rapamycin treatment targeting three unmet medical needs in lung transplant patients: bronchiolitis obliterans syndrome (BOS), pulmonary hypertension-interstitial lung disease (PH-ILD), and severe acute pulmonary hypertension (SAPH), with promising phase data showing potential reversal of BOS. The company has operational runway through 2028 with major data readouts expected in 2027-2028, but clinical development timelines and regulatory approval risks remain significant uncertainties.